Navigation Links
Anesiva Announces First Quarter 2008 Financial Results

$1 $-

Operating expenses:

Research and development 13,384 6,962

General and administrative 8,457 5,754

Total operating expenses 21,841 12,716

Loss from operations (21,840) (12,716)

Interest and other income 248 1,038

Loss before minority interest (21,592) (11,678)

Minority interest in loss of variable

interest entity 9 -

Net Loss (21,583) (11,678)

Basic and diluted net loss per common share $(0.54) $(0.43)

Shares used to compute basic and diluted

net loss per common share 40,269 27,315

Stock-based compensation $1,562 $2,047

Anesiva, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

March 31, December 31,

2008 2007

(unaudited) (Note)


Cash, cash equivalents and short-term

investments $70,043 $90,840

Other current assets 3,193 2,225

Total current assets 73,236 93,065

Property and equipment, net 15,602 15,276

Other assets, non-current 1,381 1,395

Total assets $90,219 $109,736

Liabilities and stockholders' equity

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... Talon Innovations, a provider of ... other technology-driven industries, announces that it is one of three finalists for the Minnesota ... On Thursday, September 25 Talon Innovations was recognized as a nominee for this ...
(Date:10/7/2015)... PUNE, India , October 8, 2015 ... --> Medical biotechnology accounts for ... use of bioinformatics in drug discovery and ... with . ... --> On the basis of applications, ...
(Date:10/7/2015)... , ... October 07, 2015 , ... ... ) will present a public educational seminar on the latest advances in ... 10th from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town Square ...
Breaking Biology Technology:
... announces the following Webcast:, What: Transgenomic Inc. ... Conference Call, When: Thursday, February ... , How: Live over the Internet -- ... address above., To access the call via ...
... Pharsight,s Regulatory-Oriented Consulting Unit to Use Pharsight, ... Pre-Clinical and Clinical Data, MOUNTAIN VIEW, ... PHST ), a leading provider of software, ... drug,development, today announced that its Reporting and ...
... (Nasdaq: MEMY ) announced today that it will report,its fourth quarter ... U.S. financial markets open. Management will provide a,Company update and discuss the ... a.m. EST., Investors and other interested parties may ... ...
Cached Biology Technology:
(Date:9/28/2015)... -- According to a new market research ... & Others), Application (Access Control & Others), Industry (Travel ... Global - Forecast to 2020", published by MarketsandMarkets, the Iris ... by 2020, at a CAGR of 23.40% between 2015 ... T ables and 66 Figures spread ...
(Date:9/24/2015)...  EyeLock LLC, a market leader of iris-based identity ... latest technology in Booth #602 at next week,s ASIS ... EyeLock,s iris authentication technology provides an unprecedented level ... it the most proven way to authenticate one,s identity ... deliver a fast and friendly user experience to identify ...
(Date:9/10/2015)... Report Details Emerging Biological ... and Revenue Prospects to Help You Stay Ahead ... new drug classes? Get the latest technological and ... market data and industry knowledge, benefitting your influence. ... and sales predictions. Visiongain,s new study reveals ...
Breaking Biology News(10 mins):
... discovered a new corticosteroid hormone in the sea lamprey, ... dating back 500 million years. These findings have shed ... help conservation and management efforts for lampreys. "This ... lamprey conservation," says principal investigator and lead author David ...
... graham crackers might be one way to get children to ... of Minnesota shows. Federal nutrition guidelines recommend at least ... have found that children typically only eat about one serving ... texture of whole-grain foods. In this study, researchers served ...
... Allergy and Infections Disease has awarded a five-year ... is leading a consortium of academic medical centers ... atopic dermatitis. The researchers will focus on antibiotic-resistant ... of the skin, both of which are more ...
Cached Biology News:
Request Info...
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: